Test drug KM1 for repeat or resistant ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This early-phase study tests whether KM1 is safe and can shrink or control ovarian, fallopian tube, or primary peritoneal cancer that has come back or not responded to standard treatment. It may help people who have limited options, but eligibility is strict to keep participants safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have epithelial ovarian, fallopian tube, or primary peritoneal cancer confirmed by lab tests (but not mucinous cancer).
- Your cancer has come back or is resistant after at least one standard platinum chemotherapy regimen.
- Your current condition is fairly strong: ECOG 0 or 1, and you’re expected to live at least 3 months.
- Side effects from prior treatment must be mostly back to baseline (typically Grade 1 or lower, with a few exceptions).
- Your scans must show at least one measurable tumor spot, and your kidneys, liver, blood counts, clotting, and immune blood cells must be adequate.
- If you can get pregnant, you must have a negative pregnancy test and use reliable birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a new targeted drug (SHR-A1811) against standard chemotherapy for ovarian cancer that no longer responds to platinum drugs. It's for people whose tumors have a specific protein called HER2, and who have had limited prior treatments after platinum resistance.
This study tests a new oral drug called NMS-03305293 for women with recurrent ovarian cancer. It may work by targeting a specific protein involved in cancer growth. You may be eligible if you have high-grade serous ovarian cancer, have had limited prior treatments, and do not have a BRCA mutation.
This Phase 1 study tests whether giving your own immune cells—engineered to target the FSH receptor—can control recurrent ovarian-related cancers. It’s mainly looking at safety and early signs of activity for patients whose cancer has not responded well to standard platinum chemotherapy.
This trial tests a new drug called JSKN003 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if this drug can shrink tumors or slow cancer growth. If you qualify, you may receive this experimental treatment and be closely monitored by a study team.
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.